Edition:
United States

Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Jintian Pharmaceutical Group Ltd announces acquisition of 4.99pct equity interest in Jintian Aixin Medicine Distribution Co., Ltd


Monday, 25 Aug 2014 09:26am EDT 

Jintian Pharmaceutical Group Ltd:To acquire 4.99pct equity interest of Jintian Aixin Co. by the end of Aug. 2014.Enters into the acquisition agreement in relation to the acquisition at the consideration of about 67.5 million yuan (equivalent to about HK$85.1 million).Says it currently legally holds 95.01pct equity interest in Jintian Aixin Co. and the Vendor legally holds 4.99pct equity interest in Jintian Aixin Co. for and on behalf of the purchaser through the structured contracts.Upon completion, it will legally and beneficially hold 100pct equity interest of Jintian Aixin Co. 

Company Quote